Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 25, 2025, titled "Glenmark Pharmaceuticals Announces Launch of Nebzmart® GFB Smartules® and GlenmarkAirz® FB Smartules®, World s First Nebulized Triple Therapy for COPD".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals has announced the launch of Nebzmart® GFB Smartules® and GlenmarkAirz® FB Smartules®, claimed to be the world's first nebulized triple therapy for Chronic Obstructive Pulmonary Disease (COPD). The products use Glenmark's proprietary Smartules® technology platform, delivering three drugs in a single nebulized formulation. This is a first-in-class innovation in the respiratory segment, targeting a large patient population suffering from COPD. The launch strengthens Glenmark's respiratory portfolio and its position in India's pharmaceutical market.
Positive near-term sentiment for the stock, highlighting innovation and first-to-market advantage in a high-demand therapy area. Could drive incremental respiratory segment revenue and reinforce Glenmark's brand as a respiratory-focused player.